Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Palforzia garnered favorable AdComm votes on efficacy and safety.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers